Decoding Cancer Plasticity for
Human-Relevant Drug Response.

Delivering early insights into treatment efficacy and resistance using next-generation functional assays with exceptional biological fidelity.

Explore our pipeline

90%

of drug candidates fail in human trials.

Late-stage resistance and poor predictivity derail the majority of therapies.

3–5%

of cancer drugs entering trials ever reach approval.

The success rate in oncology remains critically low.

€50–60B

lost annually in failed oncology R&D.

Billions are spent advancing therapies that ultimately do not translate.

50–100M

animals used every year in research.

Yet existing models still fail to reliably predict human cancer behaviour.

Cancer Drug Failure Isn't About Wrong Targets.
It's About Undetected Adaptation.

Oncology failure is not driven only by incorrect targets. It is driven by the ability of cancer to evolve under therapeutic pressure.

Most screening systems measure early response, but they do not assess how tumors adapt and develop resistance. These escape mechanisms often remain undetected until after extensive and costly animal studies, or even during clinical trials, while important development decisions are based on short-term data.

This gap increases risk, cost, and lost opportunity.

Cancer cells undergoing adaptive changes

Cymoplive Reveals What Is Difficult to Detect in Conventional Models

Cancer cells often do not simply die in response to therapy. Instead, they survive through adaptive, non-genetic changes that are difficult to detect in conventional models.

Cymoplive makes these dynamic cellular adaptations visible for the first time ever, enabling the identification of resistance mechanisms that typically remain undetected in early screening systems.

Our Pipeline

Breakthrough Discoveries

MarGel™

Our proprietary organ-like hydrogel engineered to recreate human-relevant physiological conditions and preserve tumour heterogeneity as observed in human cancers.

OncoTrix™

OncoTrix™ is a first-in-class platform that uses structured conditions to reveal functional adaptive behaviours of cancer cells missed by existing systems.

CellTraceD™

Live behavioural scoring that converts adaptive behaviour into actionable measures of cancer aggressiveness, drug efficacy pharmacodynamics, resistance/relapse risk, and combination performance.

Advancing Predictive Oncology Models

Cymoplive is a proprietary platform that delivers time-resolved insights into tumor adaptive behaviour under controlled experimental conditions.

Our platform and analytical framework have been validated in human carcinoma models, including pancreatic, triple-negative breast, and cervical cancers, demonstrating robust and reproducible performance across indications.